ID   XMMCO-791
AC   CVCL_F815
SY   791
DR   CLO; CLO_0009650
DR   ATCC; HB-9173
DR   Wikidata; Q54994847
RX   DOI=10.3390/antib1010039;
RX   Patent=US4708862;
RX   Patent=US4925922;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9173.
CC   Biotechnology: Was used to produce monoclonal antibody MoAb 791T which when conjugated to ricin chain A produces XomaZyme-791 (79IT/36-RTA). XomaZyme-791 was evaluated in two phase 1 clinical trials to treat patients with metastatic colorectal carcinoma (DOI=10.3390/antib1010039).
CC   Monoclonal antibody isotype: IgG2b.
CC   Monoclonal antibody target: Human colorectal tumour-associated antigen.
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_2155 ! P3/NS1/1-Ag4.1
CA   Hybridoma
DT   Created: 11-02-13; Last updated: 21-03-23; Version: 6
//
RX   DOI=10.3390/antib1010039;
RA   Becker N., Benhar I.;
RT   "Antibody-based immunotoxins for the treatment of cancer.";
RL   Antibodies 1:39-69(2012).
//
RX   Patent=US4708862;
RA   Baldwin R.W.;
RT   "Radioimmuno detection of human cancers using anti-tumor monoclonal
RT   antibody.";
RL   Patent number US4708862, 24-Nov-1987.
//
RX   Patent=US4925922;
RA   Byers V.S., Baldwin R.W., Scannon P.J.;
RT   "Potentiation of cytotoxic conjugates.";
RL   Patent number US4925922, 15-May-1990.
//